CorMedix Inc Completes REZZAYO Phase III Clinical Trial Enrollment

Summary

CorMedix Inc announced the completion of enrollment in the Phase III RESPECT clinical trial for Rezzayo, with topline results expected in Q2 2026.Reuters

Impact Analysis

So basically, CorMedix Inc is hitting a pivotal point with the completion of enrollment for its Phase III trial of Rezzayo. This is a big deal because it sets the stage for topline results expected in Q2 2026, which could be a major catalyst for the stock. The timing is interesting—wrapping up enrollment now gives them a clear runway to focus on data analysis and potential regulatory discussions. The market might be underestimating the significance of this milestone, especially if the results are positive. The real story here is about execution risk and whether CorMedix can deliver compelling data that meets or exceeds expectations. If they do, it could significantly enhance their competitive position and open up new revenue streams. Keep an eye on how competitors react and any shifts in market sentiment as we approach the results announcement.Reuters